Skip to content
December 03, 2022

Equity.Guru

Investment information for the new generation

MMED.NEO

On Tuesday September 27th 2022, psychedelics company MindMed (MMED.NE) announced the pricing of a public offering of common shares and warrants. An offering that the market saw as highly…
Some positive action on psychedelic stocks in the last few days. As a technical analyst, there are good signs indicating a reversal is occurring. The downtrend is over, and…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January.  The fund closed…
Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential to muddy the market,…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board. Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went…